Clin Osteol 2019; 24(4): 219-222

První biosimilár k léčbě osteoporózy v EU schválen!Advertorial

Vaněk Martin
CZECH HEALTH MEDIA s. r. o., Praha

Received: November 6, 2019; Published: December 11, 2019  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vaněk M. První biosimilár k léčbě osteoporózy v EU schválen! Clinical Osteology. 2019;24(4):219-222.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Takács I, Jókai E, Kováts DE et al. The first biosimilar approved for the treatment of osteoporosis: results of a comparative pharmacokinetic/pharmacodynamic study. Osteoporos Int 2019; 30(3): 675-683. Dostupné z DOI: <https://doi.org/10.1007/s00198-018-4741-0>. Go to original source...
    2. Kovács P, Schäfer T, Háda V et al. Comparative Physicochemical and Biological Characterisation of the Similar Biological Medicinal Product Teriparatide and Its Reference Medicinal Product. BioDrugs 2020; 34(1): 65-75. Dostupné z DOI: <https://doi.org/10.1007/s40259-019-00386-x>. Go to original source...
    3. Hagino H, Narita R, Yokoyama Y et al. A multicenter, randomized, rater-blinded, parallel-group, phase 3 study to compare the efficacy, safety, and immunogenicity of biosimilar RGB-10 and reference once-daily teriparatide in patients with osteoporosis. Osteoporos Int 2019; 30(10): 2027-2037. Dostupné z DOI: <https://doi.org/10.1007/s00198-019-05038-y>. Go to original source...

    Return to the content


    Clinical Osteology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.